论文部分内容阅读
目的探讨糖皮质激素与特布他林治疗慢性阻塞性肺疾病(COPD)急性加重期的临床效果及安全性。方法选取2014年6月—2015年8月江西农业大学附属医院收治的COPD急性加重期患者160例,按照患者的入院先后顺序分为研究组与参照组,各80例。参照组患者给予特布他林雾化吸入治疗,研究组患者在参照组基础上联合糖皮质激素丙酸氟替卡松治疗,比较两组患者临床疗效、肺泡换气量、血氧分压及不良反应发生情况。结果研究组患者总有效率高于参照组,差异有统计学意义(P<0.05)。治疗前两组患者肺泡换气量比较,差异无统计学意义(P>0.05);治疗后研究组患者肺泡换气量高于参照组,差异有统计学意义(P<0.05);治疗后两组患者肺泡换气量高于治疗前,差异有统计学意义(P<0.05)。治疗前两组患者血氧分压比较,差异无统计学意义(P>0.05);治疗后研究组患者血氧分压高于参照组,差异有统计学意义(P<0.05);治疗后两组患者血氧分压高于治疗前,差异有统计学意义(P<0.05)。研究组患者不良反应发生率低于参照组,差异有统计学意义(P<0.05)。结论糖皮质激素与特布他林治疗COPD急性加重期的临床效果确切,可有效改善患者肺通气功能,且不良反应少。
Objective To investigate the clinical effects and safety of glucocorticoid and terbutaline in the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD). Methods From June 2014 to August 2015, 160 cases of acute exacerbation of COPD were admitted to Affiliated Hospital of Jiangxi Agricultural University. They were divided into study group and reference group according to the sequence of admission. Patients in the reference group were treated with inhalation of terbutaline. Patients in the study group were treated with glucocorticoid fluticasone propionate on the basis of the reference group. Clinical efficacy, alveolar ventilation, partial pressure of oxygen and adverse reactions were compared between the two groups Happening. Results The total effective rate of study group was higher than that of reference group, the difference was statistically significant (P <0.05). There was no significant difference in the alveolar ventilation between the two groups before treatment (P> 0.05). After treatment, the alveolar ventilation in the study group was higher than that in the reference group (P <0.05) Group alveolar ventilation than before treatment, the difference was statistically significant (P <0.05). There was no significant difference in the partial pressure of oxygen between the two groups before treatment (P> 0.05). After treatment, the partial pressure of blood oxygen was higher in the study group than in the reference group (P <0.05) The partial pressure of blood oxygen in patients was higher than that before treatment, the difference was statistically significant (P <0.05). The incidence of adverse reactions in the study group was lower than that in the reference group, the difference was statistically significant (P <0.05). Conclusion The clinical effect of glucocorticoid and terbutaline in the treatment of acute exacerbation of COPD is exact, which can effectively improve the pulmonary ventilation and reduce the adverse reactions.